20.07.30-Vetoquinol Slideshow 2020 H1 Results

EBITDA, ongoing value creation H1 2020 Results 21 €m 06/30/2020 06/30/2019 Net income before equity method 14.8 12.8 Income tax expense 7.6 4.9 Net financial income/(expense) 0.5 0.3 Provisions recorded under non-recurring operating income and expenses 2.1 (0.2) Provisions and write-backs 0.3 (0.3) Depreciation 10.2 6.7 Depreciation - IFRS 2.4 2.1 EBITDA 38.0 26.2 › Impact of deprecation of acquired assets (€ 3.7m vs €1.3m) › EBITDA = 19.4% of H1 2020 sales

RkJQdWJsaXNoZXIy NTkwMjY=